NEWS
News Updates
Big News! The Center for Drug Evaluation of the National Medical Products Administration has released the “Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2022).”
Release time:
2023-09-22 15:06
Source:
https://www.cde.org.cn/main/news/viewInfoCommon/46260e34bfe67292bfae1de8863d20fe
To gain a comprehensive understanding of the progress of clinical trials for new drug registrations in China, leverage information technology to enhance drug regulatory capabilities, promptly disclose information on clinical trial progress to the public, and provide reference for new drug research and development, resource allocation, and drug review and approval processes, the Center for Drug Evaluation has conducted a thorough compilation and analysis of the current status of clinical trials for new drug registrations in China in 2022, based on the new drug clinical trial registration data from the Drug Clinical Trial Registration and Information Disclosure Platform. As a result, the “Annual Report on the Progress of Clinical Trials for New Drug Registrations in China (2022)” has been prepared.
This annual report provides a comprehensive analysis of the overall trends and key characteristics of clinical trials conducted in 2022, based on information from drug clinical trial registrations for that year. The analysis covers various aspects, including drug type, product category, indications, sponsor type, registration classification, trial classification, trial phase, trials involving special populations, clinical trial sites, time to first registration of clinical trials, time to trial initiation, Data Monitoring Committee (DMC) involvement, and trial completion status. In addition, the report includes analyses of cell and gene therapy products, medical imaging products, the time taken for applicants to submit their first clinical trial registrations, and an analysis of clinical trials associated with innovative drugs approved for market launch in 2022.
Attachment: Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2022)
Center for Drug Evaluation, National Medical Products Administration
September 7, 2023
Related attachments
| Serial number | Attachment Name |
|---|---|
| 1 | Annual Report on the Progress of Clinical Trials for New Drug Registration in China (2022).pdf |
Recommended Services
2020-09-25
Eurasia Huizhi boasts more than ten Phase I strategic collaboration centers, providing high-quality, specialized resources for early-phase clinical studies of innovative drugs. For each project, our expert medical team drafts initial clinical study protocols, consults with clinical experts in relevant fields, and develops clinically feasible and regulatory-compliant implementation plans. The company has extensive experience in conducting clinical trials for a variety of new drugs, including chemical drugs, traditional Chinese medicines, and biologics. Our services include: 1) Feasibility Assessment: Clinical trial feasibility evaluation, identification of centers/researchers, and center feasibility assessment & qualification review. 2) Medical and Clinical Strategy & Planning: Clinical trial planning & execution, risk identification & management.
2020-09-25
Opinions of the General Office of the State Council on Conducting Evaluations of the Quality and Efficacy Consistency of Generic Drugs (Guobanfa [2016] No. 8) Generic drugs that were approved for marketing prior to the implementation of the new classification system for chemical drug registration—and which have not been approved in accordance with the principle of consistency in quality and efficacy with the originator drugs—must undergo consistency evaluations. The consistency evaluation of generic drugs refers to the phased and batch-wise assessment of the quality consistency of generic drugs already approved for marketing, based on the principle of consistency in quality and efficacy with the originator drugs. In other words, generic drugs must achieve a level of quality and efficacy that is consistent with the originator drugs. The purpose of conducting these consistency evaluations is to ensure that generic drugs are comparable to the originator drugs in terms of both quality and efficacy.
Leave a message for inquiry
Follow us
Address: Room 3008, Building I, Yingkun Century, No. 6 Courtyard, East Road of the Automobile Museum, Fengtai District, Beijing
Phone: +86 10 86229816 Fax: 010-83739030
Email: bd-oyhz@healtech.com.cn (Business Cooperation)
ouyahuizhi-hr@healtech.com.cn (Resume Submission)
Follow the official account
WeChat Official Account
Friendship Links:Beijing Aotekang Pharmaceutical Technology Development Co., Ltd. Suzhou Suhao Biomaterials Technology Co., Ltd. Beijing Dikang Pharmaceutical Investment Management Co., Ltd. Center for Drug Evaluation, National Medical Products Administration National Medical Products Administration
Copyright © Eurasia Huizhi (Beijing) Medical Research Co., Ltd.